Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Neuroblastoma 10Melanoma 8Neoplasm Metastasis 6Breast Neoplasms 6Ganglioneuroblastoma 5Triple Negative Breast Neoplasms 4Prostatic Neoplasms 4Multiple Myeloma 4Lymphoma 4Lung Neoplasms 4Carcinoma, Non-Small-Cell Lung 4Myelodysplastic Syndromes 3Lymphoma, Non-Hodgkin 3Leukemia, Myeloid, Acute 3Leukemia, Myelogenous, Chronic, BCR-ABL Positive 3Glioblastoma 3Carcinoma, Renal Cell 3Brain Neoplasms 3Uveal Melanoma 2Pancreatic Neoplasms 2Osteosarcoma 2Oligodendroglioma 2Neoplasms 2Medulloblastoma 2Lymphoma, Follicular 2Leukemia 2Gliosarcoma 2Glioma 2Carcinoma, Intraductal, Noninfiltrating 2Astrocytoma 2

Interventions

Temozolomide 11Cyclophosphamide 11Radiotherapy 7Magnetic Resonance Spectroscopy 6Filgrastim 6Cisplatin 6Vincristine 5Etoposide 5Carboplatin 5antineoplaston AS 2-1 4antineoplaston A10 4sargramostim 3Thiotepa 3Melphalan 3Carmustine 3Automobiles 32-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole 3gallium Ga 68 dotatate 2fludarabine 2dactolisib 2aldesleukin 2Thalidomide 2TH 302 2Surveys and Questionnaires 2Paclitaxel 2Irinotecan 2Granulocyte Colony-Stimulating Factor 2Gemcitabine 2Gadolinium DTPA 2Everolimus 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neuroectodermal Tumors, Primitive × Colony-Stimulating Factors × Clear all
NCT02444546 2023-04-24

Wild-Type Reovirus in Combination With Sargramostim in Treating Younger Patients With High-Grade Relapsed or Refractory Brain Tumors

Mayo Clinic

Phase 1 Completed
6 enrolled
CNS

Diffuse Intrinsic Pontine Glioma, Astrocytoma, Brain Neoplasms, Glioma, Medulloblastoma, Oligodendroglioma, Neuroectodermal Tumors, Primitive, Rhabdoid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡